gutflix
GI learning, personalised

Summary

EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Jaroslaw Kierkus

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

In the Phase 3 QUASAR Induction Study, guselkumab 200mg IV demonstrated early and progressive symptom improvement versus placebo in patients with moderately to severely active ulcerative colitis, with statistically significant benefits emerging as early as Week 2.

KEY POINTS

- At Week 12, symptomatic response was achieved in 71.7% of guselkumab-treated patients versus 35.0% with placebo (treatment difference 37.0%, p<0.001), and symptomatic remission in 49.9% versus 20.7% (treatment difference 29.4%, p<0.001).
- Statistically significant improvements in stool frequency and rectal bleeding were observed as early as Week 2 and increased progressively through Week 12 in guselkumab-treated patients.
- The study enrolled 701 patients with mean UC duration 7.5 years, 67.9% with severe endoscopic disease, and 49.1% with prior inadequate response or intolerance to advanced therapies.
- Mean reduction in absolute number of stools per day at Week 12 was -3.15 with guselkumab versus -1.36 with placebo (treatment difference -1.78, p<0.001), and 64.6% versus 28.6% achieved rectal bleeding subscore of 0.
- This material would be most relevant to gastroenterologists managing moderate to severe ulcerative colitis, particularly in patients with prior advanced therapy failure.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/911c2042-743b-11ee-915b-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.